Q BioMed (OTCQB: QBIO) News: Mannin Research to
Present Glaucoma Therapeutics Treatment at MedCity INVEST Chicago
Management to
Present Lead drug candidate to Industry and Venture Finance Executives
NEW
YORK - April 12, 2016 (Investorideas.com Newswire) Q BioMed Inc. (OTC: QBIO),
a biotechnology acceleration company is pleased to announce that its license
technology partner, Mannin Research, will present at MATTER Midwest University
HealthTech Showcase on April 12-13th, 2016. Mannin Research will present and
discuss its glaucoma treatment technology at the forum to an audience of
sophisticated healthcare investors.
The
showcase is part of the opening reception for the MedCity INVEST conference.
MedCity INVEST (formerly the MidAmerica Healthcare Venture Forum) is a national
healthcare investing conference based in Chicago. MedCity INVEST is the premier
national healthcare investing conference based in the Midwest, uniting active
investors with corporate business development executives to facilitate
investment opportunities with promising startups. For more than a decade,
biotech, medical device, digital health, diagnostics, pharma and beyond have
presented there to investors like AbbVie, Qualcomm Ventures, Mayo Clinic
Ventures, Baxter, Baird, Venture Investors and beyond.
More
than 300 industry leaders, venture capitalists and angel investors will be in
attendance April 11-13 to discuss investment trends and interact with a number
of promising early-stage start-up companies.
As
part of their involvement with the Chicago-Canada Mentorship Program (C2MP),
Mannin Research will be attending the MedCity INVEST conference. Mannin
Research Inc. has also been selected to participate in the MATTER Midwest
University HealthTech Showcase as part of the CIM@MATTER group of companies
attending. MATTER is showcasing their top healthcare technologies at the
official opening reception for the MedCity INVEST Conference. For more
inforamtion on the event please visit their website
Mannin's
CEO, Dr. George N. Nikopoulos stated, "We are looking forward to
discussing Mannin's innovative solution for the treatment of glaucoma with
industry leaders and investors at the Showcase on Monday and throughout the
MedCity invest conference this week. This opportunity would not be possible
without the C2MP and the CIM@MATTER program teams, and we thank them for their
support."
Denis
Corin, CEO of Q BioMed Inc. said, "This is a unique opportunity to present
our innovative glaucoma therapeutic platform to pharma industry executives,
venture capital funds and angel investors."
In
October 2015 Q BioMed Inc entered into an agreement with Mannin Research to
exclusively license, with an option to acquire, the platform technology assets
of Mannin Research, the developer of a new class of vascular therapeutics.
Mannin's primary focus is developing a first-in-class therapeutic eye-drop for
glaucoma in adults and children, using a research platform designed to help
develop new drugs for that indication and cystic kidney disease, among other
diseases. Lead drug candidate MAN-01 is designed to treat abnormal vessels
within the eye - thus treating glaucoma at its root causes.
We
invite our shareholders and interested parties to subscribe to our email list
and stay informed on our website at http://www.qbiomed.com and follow us on
the social media feeds we use.
About Q BioMed Inc.
Q BioMed Inc. ”Q“ is a biomedical acceleration and
development company. We are focused on acquiring companies and biomedical
assets. Q is dedicated to providing these target companies and assets,
strategic resources, developmental support, and expansion capital to ensure
they meet their developmental potential enabling them to provide products to patients
in need.
Forward-Looking
Statements:
This
press release may contain “forward-looking statements” within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements include, but are not limited to, any
statements relating to our growth strategy and product development programs and
any other statements that are not historical facts. Forward-looking statements
are based on management’s current expectations and are subject to risks and
uncertainties that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause actual results to
differ materially from those currently anticipated are: risks related to our
growth strategy; risks relating to the results of research and development
activities; our ability to obtain, perform under and maintain financing and
strategic agreements and relationships; uncertainties relating to preclinical
and clinical testing; our dependence on third-party suppliers; our ability to
attract, integrate, and retain key personnel; the early stage of products under
development; our need for substantial additional funds; government regulation;
patent and intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation or
undertaking to release publicly any updates or revisions to any forward looking
statements contained herein to reflect any change in our expectations or any
changes in events, conditions or circumstances on which any such statement is
based, except as required by law.
Contact:
Denis Corin
CEO
Q BioMed Inc.
1 888 357 2435
Sign up for the
free investor news and stock alerts:
This
news is published on the Investorideas.com Newswire - a global digital news
source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party
sourced news, articles and equity research as well as creates original content,
including video, interviews and articles. Original content created by
investorideas is protected by copyright laws other than syndication rights. Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investment involves risk and
possible loss of investment. This site is currently compensated for news
publication and distribution, social media and marketing, content creation and
more. Contact each company directly regarding content and press release
questions. Disclosure is posted for each compensated news release, content
published /created if required but otherwise the news was not compensated for
and was published for the sole interest of our readers and followers. More
disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure:
QBIO has retained investorideas.com for PR, media, news publication and social
media effective February 5th for three months: two thousand five hundred per
month.
Additional info regarding BC Residents and global Investors:
Effective September 15 2008 - all BC investors should review all OTC and Pink
sheet listed companies for adherence in new disclosure filings and filing
appropriate documents with Sedar. Read for more info:
http://www.bcsc.bc.ca/release.aspx?id=6894. Global
investors must adhere to regulations of each country.
No comments:
Post a Comment